Galmed Pharmaceuticals Ltd. (NASDAQ:EOCN – Get Free Report) was the target of a large decline in short interest in the month of October. As of October 15th, there was short interest totaling 7,516 shares, a decline of 46.7% from the September 30th total of 14,112 shares. Approximately 0.9% of the shares of the company are sold short. Based on an average daily volume of 9,029 shares, the days-to-cover ratio is currently 0.8 days.
Galmed Pharmaceuticals Price Performance
EOCN traded down $0.23 during trading on Monday, hitting $2.87. 9,806 shares of the stock traded hands, compared to its average volume of 149,243. Galmed Pharmaceuticals has a twelve month low of $2.33 and a twelve month high of $12.32. The company has a market cap of $2.98 million, a price-to-earnings ratio of -0.19 and a beta of 0.70. The business has a 50 day moving average price of $4.05 and a 200 day moving average price of $4.71.
Galmed Pharmaceuticals (NASDAQ:EOCN – Get Free Report) last released its quarterly earnings data on Wednesday, September 2nd. The biopharmaceutical company reported ($2.86) earnings per share for the quarter, beating the consensus estimate of ($3.12) by $0.26.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a report on Thursday, October 15th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, Galmed Pharmaceuticals presently has an average rating of “Sell”.
Get Our Latest Stock Report on Galmed Pharmaceuticals
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
Further Reading
- Five stocks we like better than Galmed Pharmaceuticals
- AbbVie’s Humira Era Is Fading, But Its New Growth Engines Face Another Test
- GLP-1 Focus or Broader Peptide Exposure: Which ETF Has the Edge?
- Mortgage Rates Froze U.S. Housing, But These 3 Overseas Markets Still Pay Double Digits
- Big Tech Is Spending Billions on AI—These 5 Stocks Are Getting Paid
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
